Skip to content
  • Home
  • Health & Tech
  • FDA & EMA
  • Oncology
  • Contact

Pharminent

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure

 May 29, 2025

iTeos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

Post navigation

FDA approves Eton’s application for hydrocortisone oral solution →
← Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities

RSS News – European Pharmaceutical Review

  • Roche reports long-term capabilities of multiple sclerosis drug May 30, 2025
  • New technology could enhance CAR T therapy manufacture May 29, 2025
  • New Eli Lilly acquisition to progress potential next-generation pain treatment May 28, 2025
  • CHMP meeting highlights – May 2025 May 27, 2025
  • Major trial indicates potential of novel hypertension drug May 26, 2025
  • FDA approval marks shift in diabetic retinopathy treatment May 23, 2025

RSS Big Molecule Watch

  • FDA Approves Bio-Thera and Hikma’s Ustekinumab Biosimilar May 29, 2025
  • FDA Approves BLA for Novavax’s COVID-19 Vaccine May 23, 2025
  • Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody May 21, 2025
  • HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation May 21, 2025
  • Regeneron Awarded $407 Million in Amgen Antitrust Suit May 19, 2025

RSS Drug Channels

  • Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
  • Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
  • How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
  • What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025
  • Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025
  • How Large PBMs Make Money Today: A 2025 Drug Channels Update May 13, 2025
  • From Barriers to Bridges: Rethinking Medication Access for 2025 May 9, 2025

Sign Up to Receive Updates

Check your inbox or spam folder to confirm your subscription.

@ 2025 Pharminent. All rights reserved

Design by ThemesDNA.com